Home » 2017 » September

Cetya Therapeutics Announces STTR Grant Award

  Cetya Therapeutics, Inc. announces the award of a $240,000 Phase I STTR grant over a 12-month period to support the in vitro assessment of its histone deacetylase inhibitors for upregulation of fetal hemoglobin as a potential treatment modality for

Learn More »